ABG
DNLI icon

Ally Bridge Group’s Denali Therapeutics DNLI Stock Holding History

Ally Bridge Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,479
Closed -$125K – 26
2022
Q4 		$125K Buy
+4,479
New +$133K 0.12% 30

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Ally Bridge Group's DNLI Position: Q1 2023 in Review

Ally Bridge Group sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 4,479 shares — an estimated $125K sold.

Ally Bridge Group first reported a position in DNLI in Q4 2022 and held it in 1 quarter. The position peaked at $125K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Ally Bridge Group reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ally Bridge Group sold 4,479 Denali Therapeutics shares in Q1 2023, an estimated $125K.
  • Ally Bridge Group first reported a position in Denali Therapeutics in Q4 2022 and held it in 1 quarter.
  • Ally Bridge Group's Denali Therapeutics position peaked at $125K in Q4 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.